Cite
380P Tumour naïve circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial.
MLA
Day, D., et al. “380P Tumour Naïve Circulating Tumour DNA (CtDNA) Analysis in Patients (Pts) with Resected Colorectal Cancer (CRC) in the Phase III ASCOLT Trial.” Annals of Oncology, vol. 33, Sept. 2022, p. S710. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.07.518.
APA
Day, D., Starus, A., Lamik, A., Sieber, O., Begbie, S., Bonaventura, A., Rai, S., Karanth, N., Underhill, C. R., Nott, L. M., van Hazel, G., van Hagen, T., Wong, M., Saqib, A., Eastgate, M., Srivastav, R., Chia, J., Toh, H. C., Jones, F., & Segelov, E. (2022). 380P Tumour naïve circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial. Annals of Oncology, 33, S710. https://doi.org/10.1016/j.annonc.2022.07.518
Chicago
Day, D., A. Starus, A. Lamik, O. Sieber, S. Begbie, A. Bonaventura, S. Rai, et al. 2022. “380P Tumour Naïve Circulating Tumour DNA (CtDNA) Analysis in Patients (Pts) with Resected Colorectal Cancer (CRC) in the Phase III ASCOLT Trial.” Annals of Oncology 33 (September): S710. doi:10.1016/j.annonc.2022.07.518.